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OBJECTIVES We sought to identify polymorphisms in genes that predispose to restenosis.
BACKGROUND Variations in the lipoprotein lipase (LPL) gene have been implicated in a number of
pathophysiologic conditions associated with coronary heart disease. The present study
examines the impact of polymorphisms in the LPL gene on restenosis (defined by target
vessel revascularization [TVR]) in a large patient population undergoing percutaneous
coronary intervention (PCI). A mouse model for restenosis was used to further investigate
LPL’s role in restenosis.
METHODS The GENetic DEterminants of Restenosis (GENDER) project is a multicenter, prospective
study design that enrolled 3,104 consecutive patients after successful PCI. These patients
were genotyped for four different LPL gene polymorphisms. In apolipoprotein E (ApoE)*3-
Leiden transgenic mice, arterial messenger ribonucleic acid (mRNA) was used to assess LPL
expression during a cuff-induced restenotic process.
RESULTS Using multivariable analysis, carriers of the 447Ter allele of the LPL enzyme showed a lower
risk of TVR compared with 447Ser homozygotes (p  0.005). In the mouse model, LPL
mRNA levels were increased 40-fold compared with control arteries at 6 h after cuff
placement.
CONCLUSIONS The LPL C/G polymorphism (Ser447Ter), resulting in a truncation of the two C-terminal
amino acids of the mature LPL protein, appears to be an important protective factor for TVR
in humans. The role of LPL in this process was further established in a mouse model, where
LPL expression was very strongly up-regulated in the target arterial wall, suggesting a
contribution of this lipolytic enzyme to restenosis. Possibly, LPL Ser447Ter genotyping may
lead to better risk stratification and tailored therapy in the prevention of restenosis after
PCI. (J Am Coll Cardiol 2005;46:1093–100) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.071Cardiology Foundation
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tipoprotein lipase (LPL) is the rate-limiting enzyme in the
ipolysis of plasma triglyceride-rich lipoproteins in the circula-
ion. In adulthood, it is synthesized in parenchymal cells of
dipose tissue, as well as in skeletal and cardiac muscle,
ollowed by transfer to heparin sulfate-binding sites at the
ascular side of the endothelium (1). The hydrolytic function of
PL is essential for the processing of triglyceride-rich chylo-
icrons and very-low-density lipoproteins (VLDLs) to rem-
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polipoproteins to high-density lipoprotein (HDL). Further-
ore, LPL plays a key role in the receptor-mediated removal
f lipoproteins from the circulation (2). The gene coding for
PL, located on chromosome 8p22, encompasses 10 exons
nd is rather polymorphic (3). Abnormal LPL function has
een reported to be associated with a number of pathophysi-
logic conditions that underlie coronary heart disease (4,5). In
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LPL Ser447Ter Polymorphism and TVR September 20, 2005:1093–100ine, changes in LPL gene expression, or amino acid substitu-
ions as a result of point mutation in the LPL gene, affect
riglyceride and HDL cholesterol levels, which in turn are
mplicated in atherosclerotic risk (6,7).
Percutaneous coronary intervention (PCI), an important
reatment for patients with atherosclerosis, is limited by the
evelopment of restenosis, despite the advent of drug-
luting stents. There is increasing evidence that inherited
actors may partly explain the excessive risk of restenosis in
ertain patients. Identifying such patients may improve
tratification of patients to a more individually tailored
reatment (8,9).
To our knowledge, the role of LPL polymorphisms in
estenosis has thus far not been investigated. Therefore, the
urpose of the current study was to evaluate in a large
onsecutive study population whether four different well-
nown variants in the LPL gene, denoted as 93T/G,
sp9Asn, Asn291Ser, and Ser447Ter, have predictive value
oward the risk of restenosis (defined by target vessel
evascularization [TVR]) after PCI. To further establish the
ole of LPL in restenosis, we quantified LPL messenger
ibonucleic acid (mRNA) expression in the restenotic vessel
n an established mouse model for restenosis (10–12).
ETHODS
tudy design. The present study population has been
escribed previously (13). In brief, the GENetic DEtermi-
ants of Restenosis (GENDER) project was designed to
tudy the association between genetic polymorphisms and
linical restenosis. Patients were eligible for inclusion if they
ere successfully treated for stable angina, non–ST-segment
levation acute coronary syndromes, or silent ischemia by
CI. Patients treated for acute ST-segment elevation myo-
ardial infarction were excluded. All patients were treated in
of the 13 referral centers for interventional cardiology in
he Netherlands. The overall inclusion period lasted from
arch 1999 until June 2001.
The study protocol conforms to the Declaration of
elsinki and was approved by the Medical Ethics Commit-
ee of each participating institution. Written, informed
onsent was obtained from each participant before the PCI
rocedure.
he PCI procedure. Standard angioplasty and stent place-
Abbreviations and Acronyms
CABG coronary artery bypass graft surgery
HDL  high-density lipoprotein
LDL  low-density lipoprotein
LPL  lipoprotein lipase
NO  nitric oxide
PCI  percutaneous coronary intervention
PCR  polymerase chain reaction
TVR  target vessel revascularization
VLDL  very-low-density lipoproteinent were performed by experienced operators using a dadial or femoral approach. Before the procedure, patients
eceived 300 mg aspirin and 7,500 IU heparin. The use of
ntracoronary stents and additional medication, such as
lycoprotein IIb/IIIa inhibitors, was at the discretion of the
perator. In case of stent implantation, patients received
ither ticlopidine or clopidogrel for at least one month after
he procedure, depending on local practice. During the
tudy, no drug-eluting stents were used.
ollow-up and study end points. Follow-up lasted at least
ine months, except when a coronary event occurred.
atients were either seen in the outpatient clinic or con-
acted by telephone. Target vessel revascularization, either
y PCI or coronary artery bypass graft surgery (CABG), was
onsidered as restenosis and was our primary end point. An
ndependent Clinical Events Committee adjudicated the
linical events.
Events occurring within the first month were excluded
rom the analysis, as these events were attributable mainly to
ubacute stent thrombosis or occluding dissections, and less
ikely to restenosis. Data were collected with standardized
ase-report forms that were completed by the research
oordinator at each site, who was blinded to the genotype of
he patients. Representatives from the data-coordinating
enter monitored all sites.
enotyping. Blood was collected in EDTA tubes at base-
ine, and DNA was extracted after standard procedures. The
PL G/A, A/G, and C/G polymorphisms in exons 2, 6, and
, respectively, resulting in the following amino acid substitu-
ions—Asp9Asn, Asn291Ser, and Ser447Ter, respectively—
ere determined by validated multilocus genotyping assay
Roche Molecular Systems, Alameda, Califormia) (14). A
imilar method was used to detect the LPL93T/G promoter
olymorphism. All four polymorphisms were selected on the
asis of their previously described relation to coronary artery
isease and/or their influence on LPL activity (14,15). In short,
ach DNA sample was amplified in a multiple polymerase
hain reaction (PCR) using biotinylated primers. The PCR
roduct pool was then hybridized to a matching panel of
equence-specific oligonucleotide probes immobilized in a
inear array on nylon membrane strips. A colorimetric detec-
ion method based on incubation with streptavidin-horseradish
eroxidase conjugate, using hydrogen peroxide and 3,3=,5,5=-
etramethylbenzidine as substrates, was used. Operators
linded to restenosis status performed genotyping.
To confirm genotype assignments, the PCR procedure
as performed in replicate on 10% of the samples. Two
ndependent observers carried out scoring. Disagreements
1%) were resolved by further joint reading, and when
ecessary, genotyping was repeated.
ipid analysis. To study the effect of the different LPL
ariants on lipid levels, we measured plasma triglycerides,
otal cholesterol, and HDL cholesterol in a subpopulation
f patients. Cholesterol and triglyceride concentrations in
erum were measured with a fully automated Hitachi 747
Hitachi, Tokyo, Japan). The HDL cholesterol level was
etermined by a turbidimetric assay on a Hitachi 911.
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September 20, 2005:1093–100 LPL Ser447Ter Polymorphism and TVRow-density lipoprotein cholesterol was calculated accord-
ng to the equation of Friedewald et al. (16). Blood was
rawn before the PCI procedure. Two of the four partici-
ating centers (Leiden University Medical Center and
cademic Hospital Maastricht) systematically collected ex-
ra blood samples to perform additional laboratory measure-
ents to examine other predictors of restenosis.
ouse model of restenosis. We further studied LPL gene
xpression during the development of restenosis in an
stablished mouse model for diet-induced atherosclerosis.
pecifically, we analyzed LPL mRNA levels in the vessel
all of apolipoprotein E (ApoE)*3-Leiden transgenic mice
fter cuff placement (10–12). Before cuff placement, the
ice were fed a Western-type diet containing 1% choles-
erol and 0.05% cholate (Hope Farms, Woerden, the
etherlands) three weeks before surgery and continued after
urgery in order to obtain stable plasma cholesterol levels.
his diet results in a human-like lipoprotein profile (10).
emoral arteries, either cuffed or non-cuffed sham-operated,
ere pooled (two arteries per sample, two samples per time
oint), and total RNA was isolated per time point using the
rizol protocol (Invitrogen, Breda, the Netherlands). Sub-
equently, cDNA synthesis of all RNA samples was
chieved using Ready-To-Go real-time (RT)-PCR beads
Amersham Biosciences, Uppsala, Sweden). All experimen-
al procedures in mice were approved by the Animal
elfare Committee of TNO-PG, Leiden, the Netherlands.
Intron-spanning primers (forward: 5=GTGGCCGAG-
GCGAGAAC-3=, reverse:5=TCCACCTCCGTGTAA-
TCAAGA-3=) and probe (5=TTCCCTTCACCCTGC-
CGAGGTT-3=) for mouse LPL gene were designed
sing Primer Express 1.5 software (Perkin-Elmer Applied
iosystems, Foster City, California). The housekeeping
enes—hypoxanthine-guanine phosphoribosyl transferase,
yclophilin, and GAPDH—were used as controls. Real-
ime PCR was performed on an ABI Prism 7700 sequence
etection system (Perkin Elmer Biosystems, Boston, Mas-
achusetts). Cycle conditions were: 50°C for 2 min, followed
y 10 min at 95°C, amplification phase of 45 cycles of 15 s
t 95°C, followed by 1 min at 60°C. The RT-PCR analysis
as performed using RT-PCR mastermix (Eurogentec,
eraing, Belgium). Aqua-dest was incorporated as a nega-
ive control.
tatistical methodology. Deviations of the genotype dis-
ribution from that expected for a population in Hardy-
einberg equilibrium was tested using the chi-square test
ith one degree of freedom. Allele frequencies were deter-
ined by counting; the 95% confidence intervals of the
llele frequencies were calculated from sample allele fre-
uencies, based on the approximation of the binomial and
ormal distributions in large sample sizes. Polymorphisms
ot in Hardy-Weinberg equilibrium were excluded from
urther analysis.
In the first stage, the association between each LPL
olymorphism and TVR was assessed using a Cox propor-
ional regression model under a co-dominant genetic model. Lo adjustment for co-variates was performed at this stage to
llow for the assessment of their possible involvement in the
ausal pathway. If 10 patients were homozygous for a
articular allele, two groups were formed with the absence
r presence of that allele as group variable.
All polymorphisms were also assessed using dominant
nd recessive models, and the model with the lowest Akaike
nformation criterion was used in multivariable regression
nalysis (17). The LPL polymorphisms were combined into
aplotypes, and the effect of haplotypes on restenosis risk
as estimated according to the methods developed by
anck et al. (18).
Multivariable regression analysis of TVR risk was per-
ormed on all polymorphisms using a stepwise backward
election algorithm. In the final step, clinical variables
ssociated with TVR or associated with genotype were
ntered into the regression model. The Kruskal-Wallis test
as used to examine the association of the different geno-
ypes with concentrations of HDL cholesterol, low-density
ipoprotein (LDL) cholesterol, and triglyceride levels.
Animal data are presented as the mean value  SEM.
ata were analyzed using the Mann-Whitney U test. A p
alue 0.05 was considered statistically significant. Statis-
ical analysis was carried out using SPSS version 11.5.
ESULTS
atient characteristics. A total of 3,146 patients had com-
lete follow-up (99.3%), with a median duration of 9.6 months
interquartile range 3.9). A total number of 42 patients expe-
ienced an event in the first 30 days and were therefore
xcluded from further analysis, according to the protocol. In
he remaining 3,104 patients, we assessed the frequencies of
he following LPL polymorphisms; 93T/G, Asp9Asn (G/
), Asn291Ser (A/G), and Ser447Ter (C/G). Successful
NA genotyping was possible in 3,028, 3,031, 3,021, and
,054 patients, respectively. The results of the remaining
atients were missing due to a lack of DNA or inconclusive
enotyping. The frequencies of the rare93G, 9Asn, 291Ser,
nd 447Ter alleles were 0.02, 0.02, 0.03, and 0.10, respectively.
The genotype distributions were consistent with Hardy-
einberg equilibrium (p  0.05), except for the 93T/G
olymorphism. Therefore, this promoter polymorphism was
xcluded from further analysis.
Comparisons of baseline characteristics among the geno-
ypes are shown in Table 1. The low frequency of carriers of
Asn and 291Ser has prompted us to pool heterozygotes
nd homozygotes for these two LPL variants. No statisti-
ally significant differences were observed between the
roups, with the following two exceptions: heterozygotes
nd homozygotes for the allele encoding for a 291Ser
enotype had a higher rate of previous CABG (p  0.05).
urthermore, heterozygotes and homozygotes for the allele
ncoding for the 9Asn LPL variant used less lipid-lowering
edication but had a higher use of beta-blocker medication.
esion-related and procedural parameters of the genotype
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LPL Ser447Ter Polymorphism and TVR September 20, 2005:1093–100roups are presented in Table 2. The only significant
ifference was found for carriers of the allele encoding for
Asn, who were treated more often for total occlusion,
ompared with homozygotes for the common allele (p 
.05). Interestingly, homozygotes for the 447Ter genotype
resented with a high statistically significant reduction in
ultivessel disease compared with the other genotypes (p
.002). In fact, we observed a gene dosage effect emphasiz-
ng a relationship between these two parameters.
At follow-up, 304 patients (9.8%) had to undergo TVR.
e did observe a significant association between the
47Ter genotype and the rates of TVR after univariate
nalysis (relative risk [RR] 0.6, 95% confidence interval [CI]
.44 to 0.83; p  0.004). In contrast, the LPL Asp9Asn,
sn291Ser variants did not show a significant association
ith TVR (p  0.1) (Table 3).
The LPL 447Ter genotype remained associated with a
ecreased risk of TVR (RR 0.6, 95% CI 0.44 to 0.86) on
ultivariable analysis, including all three polymorphisms.
inally, in the regression model, we included patient and
ntervention-related characteristics that were previously de-
cribed as related to TVR risk or genotype (such as age,
able 1. Baseline Clinical Characteristics of Patients According t
LPL G/A (Asp9Asn) L
GG
(n  2,933)
GA/AA
(n  98) (n 
ge (yrs) 62  10.7 62  10.8 62
ale 71.3 72.4
ypertension 40.7 33.7
ypercholesterolemia 60.7 67.3
iabetes 14.5 15.3
urrent smoker 24.5 21.4
amily history of MI 35.3 34.7
revious MI 39.9 34.7
revious CABG 12.3 8.2
ipid-lowering medication 54.0 65.3*
eta-blocker medication 79.0 65.3*
p  0.05 in comparison with the other genotypes; p  not significant for all other
ercentage of patients.
Asn  asparagine; Asp  aspartic acid; CABG  coronary artery bypass graft su
able 2. Lesion and Procedural Characteristics at the Time of In
LPL G/A (Asp9Asn)
GG
(n  2,933)
GA/AA
(n  98) (
estenotic lesion 6.8 5.1
otal occlusion 13.6 21.4*
ype C lesion 25.5 32.7
roximal LAD 22.3 18.4
Cx 26.9 30.6
ultivessel disease 46.2 48.0
table angina 33.1 28.6
esidual stenosis 20% 11.6 10.2
tenting 74.5 72.4
lycoprotein IIb/IIIa antagonist 26.4 25.5
p  0.05 in comparison with the other genotypes of the same polymorphism; p 
LAD  left anterior descending coronary artery; RCx  circumflex branch of the left
merican Heart Association; other abbreviations as in Table 1.ender, diabetes, stenting, residual stenosis 20%, current
moking, total occlusion, lipid-lowering medication, beta-
locker use, multivessel disease, and previous CABG) (13).
his backward stepwise selection yielded similar results (RR
.6, 95% CI 0.44 to 0.86) (Table 4).
Furthermore, because the severity of stenosis before
ngioplasty as well as (especially) the severity of stenosis
mmediately after angioplasty are key determinants of the
isk of restenosis, we have examined the effect of pre- and
ost-procedural lesion diameter for the different genotypes
n a subpopulation of 478 patients with additional angio-
raphic data. However, pre- and post-percent stenosis
alues did not differ significantly between the three geno-
ypes of the 447 polymorphism (p  0.75 and p  0.83,
espectively).
The polymorphisms were also combined into haplotypes
or further analysis. Seven of eight possible haplotypes were
bserved (data not shown). The 9G/291A/447C haplotype
as most common in both TVR cases and controls (89.7%
nd 85.1%, respectively). A smallest RR was seen with
espect to the 9G/291A/447G haplotype (RR 0.62, 95% CI
.45 to 0.85). When evaluating bilocus haplotypes, it
Genotypes of LPL Polymorphisms
/G (Asn291Ser) LPL C/G (Ser447Ter)
6)
AG/GG
(n  155)
CC
(n  2,452)
CG
(n  571)
GG
(n  31)
.7 62  11.0 62  10.7 62  10.6 62  11.2
72.9 71.4 71.6 74.2
43.2 41.1 38.2 32.3
65.8 61.8 56.9 61.3
14.8 14.8 14.0 3.2
20.6 25.2 21.4 25.8
33.5 34.8 37.3 35.5
41.3 39.8 39.9 38.7
14.2* 11.9 13.5 9.7
53.5 55.1 51.5 45.2
75.5 78.8 77.8 71.0
arisons. Age is expressed as the mean value  SD; other variables are expressed as
LPL  lipoprotein lipase; MI  myocardial infarction; Ser  serine; Ter  stop.
ntion According to the Genotypes of the LPL Polymorphisms
A/G (Asn291Ser) LPL C/G (Ser447Ter)
,866)
AG/GG
(n  155)
CC
(n  2,452)
CG
(n  571)
GG
(n  31)
.8 5.8 7.1 5.6 3.2
.7 14.2 13.9 13.8 6.5
.7 25.2 26.1 24.5 12.9
.0 24.5 22.3 21.9 25.8
.1 26.5 27.2 26.8 12.9
.3 45.5 47.6 42.0 22.6*
.1 31.6 32.5 34.9 38.7
.7 9.2 11.3 12.2 3.2
.6 71.6 74.5 75.1 67.7
.3 28.4 26.5 25.9 22.6
nificant for all other comparisons. Variables are expressed as percentage of patients.o the
PL A
AA
2,86
 10
71.3
40.3
60.7
14.5
24.6
35.4
39.7
12.1
54.4
78.7
compterve
LPL
AA
n  2
6
13
25
22
27
46
33
11
74
26
not sig
coronary artery; type C lesion  according to American College of Cardiology and
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September 20, 2005:1093–100 LPL Ser447Ter Polymorphism and TVRecame evident that this effect was caused only by the LPL
47 variant.
Lipid profiles were investigated in a subgroup of patients
n  942, data not shown). We were not able to find a
ignificant correlation between carriers and non-carriers of
he polymorphisms investigated with regard to HDL cho-
esterol, LDL cholesterol, and triglycerides (p  0.20).
orrection of lipid levels in this subgroup analysis had no
nfluence on the association of the different polymorphisms
nd TVR.
Subsequently, we evaluated if LPL gene expression
layed a role in the development of restenosis by analyzing
rterial mRNA in an established model of restenosis in
ypercholesterolemic mice. At the time of surgery, the total
lasma cholesterol level was 13.9  3.6 mmol/l.
The mRNA encoding LPL, isolated from the cuffed right
emoral artery and untreated left femoral artery, was quan-
ified at various time points after cuff placement (Fig. 1).
he mRNA encoding LPL showed peak expression 6 h
fter cuff placement, where it showed a 40-fold increase
ompared with the normal artery. The LPL mRNA levels
ere back to baseline after 24 h of induction of the
estenotic process. Sham-operated vessels (femoral artery
repared free, but without cuff placement) showed essen-
ially the same results as non-operated vessels.
ISCUSSION
n a large, prospective, multicenter, follow-up study of
onsecutive patients, we demonstrated that the LPL
able 3. Univariate Analysis of LPL Polymorphisms in
ssociation With TVR and the Distributions of Polymorphisms
olymorphisms
No. of
Patients TVR (%)
Model
Used
p
Value
sp9Asn 3,031 Dominant 0.77
GG 9.7
GA/AA 10.4
sn291Ser 3,021 Dominant 0.62
AA 9.9
AG/GG 8.5
er447Ter 3,054 Dominant 0.004
CC 10.5
CG 7.0
GG 0
VR  target vessel revascularization; other abbreviations as in Table 1.
able 4. Multivariable Cox Regression of Clinical Variables
nd LPL Ser447Ter Polymorphism Associated With TVR
RR
95% CI
p ValueLow High
iabetes 1.52 1.14 2.01 0.004
urrent smoker 0.73 0.54 0.97 0.03
tenting 0.76 0.58 1.00 0.05
otal occlusion 1.51 1.12 2.02 0.006
esidual stenosis 20% 1.35 0.97 1.89 0.08
PL 447Ter 0.62 0.44 0.86 0.005I  confidence interval; RR  relative risk; other abbreviations as in Table 1.er447Ter variant, present in 20% of the general popu-
ation, is associated with a decreased risk of TVR after PCI
3). This polymorphism has been shown in most but not all
tudies to modulate lipid levels, as well as LPL (2,4,19–25).
n fact, it was shown that this polymorphism is associated
ith decreased triglycerides, increased HDL cholesterol,
nd a decreased risk of coronary artery disease (4,26,27).
urthermore, a recent meta-analysis confirmed that the
er447Ter variant has an effect on the lipoprotein profile, by
ecreasing plasma triglycerides and increasing HDL cho-
esterol (4). The mechanism responsible for cardiovascular
rotection and beneficial lipid profile changes observed in
his LPL variant is not entirely clear. The data suggest that
his variant may be catalytically normal with normal stabil-
ty, but may be present at higher concentrations in the
irculation associated with a higher level of LPL activity
2,4,21,28,29).
We did not find any associations for the other two
olymorphisms and TVR.
The Asp9Asn substitution at the N-terminal end is
ituated near a glycosylation site, which may influence
verall catalytic activity, whereas the Asn291Ser substitu-
ion is located in a heparin-binding cluster and may thus
ffect the interaction between LPL and the cell wall glycos-
minoglycans. Both these two amino acid substitutions are
ocated in the N-domain and likely reduce enzyme activity
nd consequently increase triglyceride levels.
The Ser447Ter substitution is located in the C-domain
nd thus may cause increased binding affinity of the trun-
ated LPL to receptors or may affect its subunit interaction,
ither facilitating or otherwise affecting the formation of
imers, which would explain the opposite effect of this
ubstitution compared with the other two, possibly forming
he basis of the observed association (4,7).
In our study, we did not find a significant association
etween the LPL447 polymorphism and HDL and LDL
holesterol and triglyceride levels (data not shown). This
ould be due to the use of lipid-lowering medications in
any of our patients.
igure 1. Messenger ribonucleic acid (mRNA) expression of lipoprotein
ipase in a cuffed femoral artery (as compared with hypoxathine-guanine
hosphoribosyl transferase mRNA expression, cuff vs. normal artery).Haplotype analyses showed that the difference in TVR
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lained by the LPL 447 variant.
In addition to the well-known role of LPL in the
ydrolysis of the triglycerides packaged in chylomicrons and
LDL, several other functions of the enzyme have recently
een identified. In particular, it has been shown that LPL
ncreases monocyte adherence via a mechanism that requires
n interaction between the C-terminal domain of the LPL,
eparin sulfate proteoglycans, and integrins (30–32). How-
ver, Zhang et al. (29) showed that the affinity of LPL
er447Ter for heparin sulfate proteoglycans was not differ-
nt from wild-type LPL. Because LPL is also expressed in
mooth muscle cells in the arterial media (33), the LPL
er447Ter polymorphism may affect the level of interaction
etween smooth muscle cells and the extracellular matrix.
he former could result in less arterial stiffness (34), leading
o more distensible arteries and thus lesser propensity for
estenosis.
On a completely different note, the LPL protein may also
nfluence vascular tone by affecting the synthesis or degra-
ation of endothelium-derived relaxing factors such as nitric
xide (NO). Endothelium-dependent vascular relaxation is
bnormal in the setting of atherosclerosis, associated with
ubnormal endothelial nitric oxide synthase (eNOS) activ-
ty, the key enzyme in basal endothelial cell NO production.
itric oxide dilates coronary arteries and promotes blood
ow by inhibiting smooth muscle contraction, platelet
ggregation, and platelet adhesion to endothelial cells by a
yclic guanosine monophosphate-mediated mechanism
35,36) In fact, LPL has been reported to increase NOS
roduction and consequential increased NO production in
ulture macrophages. Lipoprotein lipase may well have a
imilar function in vivo in both macrophages and endothe-
ial cells and may therefore have an effect on vascular tone
1,37). Therefore, mutated levels of LPL, as observed with
he Ser447Ter polymorphism, may be beneficial for endo-
helial function, an important contributor involved in reste-
osis (38).
In addition, Ziouzenkova et al. (39) found a link between
PL and peroxisome proliferator-activated receptor
PPAR) activation, suggesting that impaired LPL enzy-
atic activity might decrease endogenous PPAR-alpha
ctivation and its subsequent downstream effects, including
nti-inflammatory responses. Inflammation has been previ-
usly reported as a very important component of restenosis
40–42).
Clee et al. (43) found a decrease in blood pressure
ndependent of the lower level of triglycerides in patients
ith the LPL Ser447Ter polymorphism. Another study also
howed that the LPL Ser447Ter polymorphism was asso-
iated with lower systolic blood pressure and pulse pressure
evels in women (34). Because inflammation (40–42) and
levated blood pressure (44) have been implicated in in-
reased risk of restenosis, any positive effect of this poly-
orphism on arterial tone, inflammatory status, and ele- gated blood pressure may ultimately translate into lesser risk
or restenosis.
Because we hypothesize a potential interaction between
PL activity by genotype and inflammatory activity, we also
nvestigated several inflammatory markers, which could be
f influence on the development of restenosis and their
ffect on TVR. These markers examined are the fibrinogen
evel, the erythrocyte sedimentation rate, and C-reactive
rotein. These markers were determined in a subgroup of
atients from the GENDER project (in 753 patients for
brinogen, in 1,000 patients for the erythrocyte sedimenta-
ion rate, and in 888 patients for C-reactive protein,
espectively). All three factors, determined before PCI, did
ot have a statistically significant effect on TVR (p  0.20),
or did they influence the general results for the LPL
olymorphisms.
We further studied LPL gene expression during the
evelopment of restenosis in an established mouse model for
iet-induced atherosclerosis. In the mouse model of reste-
osis, LPL mRNA levels were increased 40-fold compared
ith control arteries at 6 h after cuff placement. This
ndicates that LPL may play an important role in the early
tages of the restenotic process development.
tudy limitations. In our study, we lack data on LPL
oncentration and LPL activity in plasma. However, we
elieve that plasma determinations have no added value,
wing to a number of reasons. Circulating LPL protein
evels were not assessed here, as basal (before PCI) plasma
easurements of the gene product are not likely to reflect
he genetically determined differences in reaction to a
rauma such as PCI. Moreover, local differences in LPL
ensitive reactions, such as those occurring in the vessel wall
t the site of PCI, cannot be measured systemically, as it is
ot yet possible to measure gene products in the vessel wall
ocally in the early phase of treatment or in the following
ays.
Furthermore, we made use of an atherosclerotic mouse
odel to study the effect of LPL on restenosis; in this
odel, we were not able to test the LPL polymorphisms
ound in humans. However, we believe that this model
ontributes to a better understanding of the involvement of
PL in the process of restenosis.
Although the mice studies can be used for analysis, it
hould be realized that perivascular cuff placement results
nitially in adventitial injury, whereas in patients with PCI,
t results in intimal injury. It is not certain to what extent
hese apparently different ways of vascular injury differ in
heir reaction regarding vascular activation and the resulting
ntimal hyperplasia.
In addition, genotyping of some patients was missing
ue to a lack of DNA or inconclusive genotyping, and
istakes could have been made in the genotyping.
owever, patients who could not be genotyped did not
iffer in any characteristic from those who could be
enotyped. Furthermore, the PCR procedure was per-
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bserved in 1% of the samples.
The 93T/G polymorphism was not in Hardy-
einberg equilibrium; the observed numbers of patients
ere 2,914 for T/T, 109 for T/G, and 5 for G/G, as
pposed to the expected number of patients: 2,910 for T/T,
17 for T/G, and 1 for G/G. This discrepancy could be
xplained by the fact that it is possible that this polymor-
hism is associated with one or more inclusion/exclusion
riteria; however, we cannot confirm this with our data, as
ll participants fulfilled those criteria. The most important
nclusion criterion was that all participants were scheduled
or PCI, and obviously the classic risk factors of cardiovas-
ular disease will be enriched in such a population. The
93T/G polymorphism is sometimes found to be especially
ssociated with HDL2 cholesterol, and ApoA-I levels with
ower levels in 93G/G carriers (45). Based on this as-
umption, one might expect more heterozygote or homozy-
ote carriers, and the latter were indeed slightly more
resent than expected.
Drug-eluting stents are now more widely used. In our
tudy, we do not have any data on these stents, as no
rug-eluting stents were used for our study, which can be
een as a limitation of our study. However, genes involved in
he process of restenosis after drug-eluting stents are prob-
bly different from the process of restenosis after bare-metal
tent placement or plain balloon angioplasty. Therefore,
ew studies are needed to investigate genes involved in the
rocess of restenosis after drug-eluting stents.
Finally, the polymorphism associated with TVR in our
tudy may be in linkage disequilibrium with other polymor-
hisms in the gene or with other nearby genes that are
ctually responsible for the development of this condition.
onclusions. We have demonstrated that LPL is signifi-
antly associated with TVR. The LPL C/G polymorphism,
hich results in a 447 Ser¡Stop (X) mutation, appears to
e an important independent protective factor in this.
urthermore, LPL mRNA was highly up-regulated in the
rst 6 h after vascular damage in a mouse model of
estenosis. Determination of this genotype could contribute
o better risk stratification and more tailored therapy for the
ndividual patient to prevent TVR after PCI.
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